Lessons from the RADAR trial

The RADAR trial is complete. Disappointingly it showed that people who gradually reduce their antipsychotic medication are more likely to relapse than people who continue it. At 2-year follow-up there were no differences in social functioning, symptoms, side effects or quality of life. Yet relapse was far from inevitable and the qualitative analysis showed that…

Contradictory responses to our review of serotonin and depression

After the publication of our umbrella review of serotonin last summer, several psychiatrists wrote letters to the journal, Molecular Psychiatry, as usually occurs after the publication of a major finding. We were invited by the editor of the journal to respond to the points raised in the letters, again a routine procedure in scientific literature.…

Systematic umbrella review finds no evidence that serotonin abnormalities are associated with depression (but don’t stop your drugs suddenly)

Our new review of serotonin research collated research from six different areas. We looked at research on serotonin levels in body fluids, levels of the main metabolite (breakdown product) of serotonin in the cerebro-spinal fluid (brain fluid), serotonin receptors, the serotonin transporter protein (the protein that removes serotonin from the synapse where it is active-…

Psychedelics – the new psychiatric craze!

Psychedelics are an increasingly fashionable medical treatment, but are they anything other than a powerful form of snake oil, or a recreational experience? Do they have any objective health benefits? Can we be confident they are safe? These questions need answering urgently as the number of people being enticed or persuaded to have these drugs is increasing. Here I draw attention to some of the issues raised by the current popularity of these drugs.